Jatin Motwani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jatin Motwani has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Ayaan Ahmed Qureshi
Liaquat National Hospital and Medical College
2 shared publications - Ihda Bani Khalaf
Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
2 shared publications - Mohammed Hammad Jaber Amin
Faculty of Medicine Alzaiem Alazhari University Khartoum Sudan
2 shared publications - Muhammad Osama Siddiqui
Liaquat National Hospital and Medical College, MBBS Karachi Pakistan
2 shared publications - Ahmad E. Saeed
School of Medicine, University of Jordan, Amman, Jordan
1 shared publication - Ahmed W. Hageen
Faculty of Medicine Tanta University Tanta Egypt
1 shared publication
Latest Publications
- 1 June 2025
- Published by Edizioni Minerva Medica in Minerva Cardiology and Angiology
- Vol. 74 (4)
Cardiac amyloidosis in severe aortic stenosis patients: an updated review unraveling their complex interplay
Aortic stenosis (AS) and cardiac amyloidosis (CA) often coexist in elderly patients, complicating diagnosis and treatment. AS is characterized by the narrowing of the aortic valve, leading to left ventricular outflow obstruction, primarily due to age-related calcification and congenital defects. CA, the most common cause of restrictive cardiomyopathy, results from amyloid protein deposits in the myocardium, causing diastolic dysfunction. Accurate diagnosis of CA in AS patients is challenging due to overlapping symptoms and the need for advanced imaging and biomarkers. Aortic valve replacement (AVR), through surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) methods, is the primary treatment for severe AS. However, the presence of CA significantly impacts perioperative risk and long-term outcomes, with increased rates of heart failure, pacemaker placement, and mortality. Despite conflicting study results, CA in AS patients is associated with poorer long-term survival and more complications. Future research should enhance AI-based diagnostics, explore novel biomarkers, and clarify AS-CA interactions. Gene-silencing therapies and optimizing perioperative management and enhancing patient education are also crucial. Addressing these challenges will improve the prognosis and quality of life for patients with concurrent AS and CA, facilitating better clinical management of this complex dual pathology.
- 1 June 2025
- Published by Edizioni Minerva Medica in Minerva Cardiology and Angiology
- Vol. 74 (4)
Cardiac amyloidosis in severe aortic stenosis patients: an updated review unraveling their complex interplay
Aortic stenosis (AS) and cardiac amyloidosis (CA) often coexist in elderly patients, complicating diagnosis and treatment. AS is characterized by the narrowing of the aortic valve, leading to left ventricular outflow obstruction, primarily due to age-related calcification and congenital defects. CA, the most common cause of restrictive cardiomyopathy, results from amyloid protein deposits in the myocardium, causing diastolic dysfunction. Accurate diagnosis of CA in AS patients is challenging due to overlapping symptoms and the need for advanced imaging and biomarkers. Aortic valve replacement (AVR), through surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) methods, is the primary treatment for severe AS. However, the presence of CA significantly impacts perioperative risk and long-term outcomes, with increased rates of heart failure, pacemaker placement, and mortality. Despite conflicting study results, CA in AS patients is associated with poorer long-term survival and more complications. Future research should enhance AI-based diagnostics, explore novel biomarkers, and clarify AS-CA interactions. Gene-silencing therapies and optimizing perioperative management and enhancing patient education are also crucial. Addressing these challenges will improve the prognosis and quality of life for patients with concurrent AS and CA, facilitating better clinical management of this complex dual pathology.
- Open Access
- 12 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (6) , 3691-3699
Anticoagulation strategies for stroke prevention in atrial fibrillation: a comprehensive review of current literature
Atrial fibrillation (AF) significantly increases stroke risk and hence requires anticoagulation for the prevention of stroke. This review discusses strategies of anticoagulation, including the paradigm shift from traditional vitamin K antagonists (VKAs), such as warfarin, to direct oral anticoagulants (DOACs): dabigatran, rivaroxaban, apixaban, and edoxaban. VKAs are effective but require regular monitoring of international normalized ratio and also pose challenges because of their drug and dietary interactions. In contrast, DOACs provide predictable pharmacokinetics, fewer interactions, and no requirement for routine monitoring, and their use is increasingly favored in clinical practice. The review puts an emphasis on the considerations that are patient-specific when choosing an anticoagulant agent, including age, renal function, and associated diseases; stroke risk or risk factors for bleeding; and it explains how tools such as the use of CHA2DS2-VASc and HAS-BLED scores can be relevant for assessing stroke and bleeding risk, respectively. Also, it is explored that the use of emerging therapies like factor XI inhibitors and combinations such as dual antiplatelet therapy with anticoagulants has the potential to provide maximum stroke prevention but fewer bleeding complications. This review evaluated the effect of reversal agents for anticoagulants that may act as a safety measure during instances of serious bleeding. In summary, AF anticoagulation has to be individually tailored based on patient characteristics and meticulous reading of clinical guidelines. As much as DOACs present a tremendous step forward in stroke prevention related to AF, future studies and emerging treatments show promise to further optimize therapeutic outcomes.
- 12 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (6) , 3691-3699
Open AccessAnticoagulation strategies for stroke prevention in atrial fibrillation: a comprehensive review of current literature
Atrial fibrillation (AF) significantly increases stroke risk and hence requires anticoagulation for the prevention of stroke. This review discusses strategies of anticoagulation, including the paradigm shift from traditional vitamin K antagonists (VKAs), such as warfarin, to direct oral anticoagulants (DOACs): dabigatran, rivaroxaban, apixaban, and edoxaban. VKAs are effective but require regular monitoring of international normalized ratio and also pose challenges because of their drug and dietary interactions. In contrast, DOACs provide predictable pharmacokinetics, fewer interactions, and no requirement for routine monitoring, and their use is increasingly favored in clinical practice. The review puts an emphasis on the considerations that are patient-specific when choosing an anticoagulant agent, including age, renal function, and associated diseases; stroke risk or risk factors for bleeding; and it explains how tools such as the use of CHA2DS2-VASc and HAS-BLED scores can be relevant for assessing stroke and bleeding risk, respectively. Also, it is explored that the use of emerging therapies like factor XI inhibitors and combinations such as dual antiplatelet therapy with anticoagulants has the potential to provide maximum stroke prevention but fewer bleeding complications. This review evaluated the effect of reversal agents for anticoagulants that may act as a safety measure during instances of serious bleeding. In summary, AF anticoagulation has to be individually tailored based on patient characteristics and meticulous reading of clinical guidelines. As much as DOACs present a tremendous step forward in stroke prevention related to AF, future studies and emerging treatments show promise to further optimize therapeutic outcomes.
- Open Access
- 30 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e78222
Reproductive Endocrine Disorders: A Comprehensive Guide to the Diagnosis and Management of Infertility, Polycystic Ovary Syndrome, and Endometriosis
Reproductive endocrine disorders, including infertility, polycystic ovary syndrome (PCOS), and endometriosis, significantly impact women’s reproductive health and overall well-being. This comprehensive review explores the diagnosis and management strategies for these prevalent conditions. Infertility, affecting millions globally, is often linked to ovulatory dysfunction, PCOS, and endometriosis. PCOS is characterized by hyperandrogenism, menstrual irregularities, and insulin resistance, contributing to anovulation and infertility. The Rotterdam criteria are widely used for PCOS diagnosis, and management includes lifestyle modifications, pharmacological treatments like ovulation inducers, and, in some cases, surgical interventions. Endometriosis, caused by the presence of endometrial-like tissue outside the uterus, leads to chronic pain and infertility through inflammation, adhesions, and impaired ovarian function. Laparoscopy remains the gold standard for diagnosing endometriosis, and treatment focuses on pain relief, fertility preservation, and reducing recurrence. In cases of endometriosis-related infertility, assisted reproductive technologies (ARTs) like in vitro fertilization (IVF) are often recommended. In addition, the role of diet and lifestyle changes in managing these conditions is gaining recognition. This review emphasizes the complexity of reproductive endocrine disorders and underscores the need for individualized treatment plans, combining medical, surgical, and lifestyle approaches to improve fertility outcomes and enhance the quality of life for affected women. The review also highlights the importance of early diagnosis and advances in therapeutic interventions to ensure optimal patient care in the management of infertility, PCOS, and endometriosis.
- 30 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e78222
Open AccessReproductive Endocrine Disorders: A Comprehensive Guide to the Diagnosis and Management of Infertility, Polycystic Ovary Syndrome, and Endometriosis
Reproductive endocrine disorders, including infertility, polycystic ovary syndrome (PCOS), and endometriosis, significantly impact women’s reproductive health and overall well-being. This comprehensive review explores the diagnosis and management strategies for these prevalent conditions. Infertility, affecting millions globally, is often linked to ovulatory dysfunction, PCOS, and endometriosis. PCOS is characterized by hyperandrogenism, menstrual irregularities, and insulin resistance, contributing to anovulation and infertility. The Rotterdam criteria are widely used for PCOS diagnosis, and management includes lifestyle modifications, pharmacological treatments like ovulation inducers, and, in some cases, surgical interventions. Endometriosis, caused by the presence of endometrial-like tissue outside the uterus, leads to chronic pain and infertility through inflammation, adhesions, and impaired ovarian function. Laparoscopy remains the gold standard for diagnosing endometriosis, and treatment focuses on pain relief, fertility preservation, and reducing recurrence. In cases of endometriosis-related infertility, assisted reproductive technologies (ARTs) like in vitro fertilization (IVF) are often recommended. In addition, the role of diet and lifestyle changes in managing these conditions is gaining recognition. This review emphasizes the complexity of reproductive endocrine disorders and underscores the need for individualized treatment plans, combining medical, surgical, and lifestyle approaches to improve fertility outcomes and enhance the quality of life for affected women. The review also highlights the importance of early diagnosis and advances in therapeutic interventions to ensure optimal patient care in the management of infertility, PCOS, and endometriosis.
- Open Access
- 16 January 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (1) , e70122
Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review
Introduction: Giant cell arteritis (GCA) is a common vasculitis predominantly affecting larger vessels, especially in individuals aged 70–79. Cerebrovascular ischemic events (CIE), such as stroke and transient ischemic attacks, are serious but rare complications of GCA, with a pooled prevalence of 4%. Some studies found that within 2 weeks of GCA diagnosis, 74% and 34% of patients experience transient or severe ischemic events, respectively.Aims: Our study aims to help physicians better manage GCA patients to reduce GCA‐related CIE by indicating important risk factors and pharmacological intervention to prevent GCA‐related CIE, particularly in the first few days of diagnosis when the risk of CIE is highest.Methods: A comprehensive literature search was conducted using Pubmed, Google Scholar, Scopus, and other relevant medical databases. As this study was a narrative review, the literature search was done in a nonsystematic manner. Studies published from 2000 to 2024 were reviewed in a nonsystematic manner for information on incidence, pathology, risk factors, pharmacological intervention, and management of GCA‐related CIE.Results: Findings indicate that age, male gender, hypertension, and smoking significantly increase the risk of GCA‐related CIE, while factors such as anemia, higher body mass index (BMI), and elevated inflammatory markers (C‐reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) appear to have protective effects. Symptoms of ischemia in the ophthalmic artery were identified as the strongest predictors of CIE. Pharmacological treatments, including glucocorticoids and tocilizumab, are instrumental in managing and potentially preventing CIE in GCA patients, with adjunctive therapies such as aspirin and antiplatelet agents also showing promise.Conclusion: GCA‐related CIE such as stroke can be very debilitating and deadly conditions, particularly when GCA is initially diagnosed. However, with early diagnosis and proper management of risk factors, GCA‐related CIE can be prevented and its severity can be reduced. Ischemia in the ophthalmic artery is found to strongly predict GCA‐related CIE while aspirin and antiplatelet agent during the first 3 months may prevent GCA‐related CIE. Risk factors such as BMI and smoking may help in stratifying the risk of GCA‐related CIE. This review underscores the importance of further studies with detailed, well‐designed approaches to risk factor analysis to strengthen these associations. Identifying these risk factors is crucial for reducing morbidity and mortality, equipping physicians to better assess and mitigate the risk of CIE in GCA patients.
- 16 January 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (1) , e70122
Open AccessRisk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review
Introduction: Giant cell arteritis (GCA) is a common vasculitis predominantly affecting larger vessels, especially in individuals aged 70–79. Cerebrovascular ischemic events (CIE), such as stroke and transient ischemic attacks, are serious but rare complications of GCA, with a pooled prevalence of 4%. Some studies found that within 2 weeks of GCA diagnosis, 74% and 34% of patients experience transient or severe ischemic events, respectively.Aims: Our study aims to help physicians better manage GCA patients to reduce GCA‐related CIE by indicating important risk factors and pharmacological intervention to prevent GCA‐related CIE, particularly in the first few days of diagnosis when the risk of CIE is highest.Methods: A comprehensive literature search was conducted using Pubmed, Google Scholar, Scopus, and other relevant medical databases. As this study was a narrative review, the literature search was done in a nonsystematic manner. Studies published from 2000 to 2024 were reviewed in a nonsystematic manner for information on incidence, pathology, risk factors, pharmacological intervention, and management of GCA‐related CIE.Results: Findings indicate that age, male gender, hypertension, and smoking significantly increase the risk of GCA‐related CIE, while factors such as anemia, higher body mass index (BMI), and elevated inflammatory markers (C‐reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) appear to have protective effects. Symptoms of ischemia in the ophthalmic artery were identified as the strongest predictors of CIE. Pharmacological treatments, including glucocorticoids and tocilizumab, are instrumental in managing and potentially preventing CIE in GCA patients, with adjunctive therapies such as aspirin and antiplatelet agents also showing promise.Conclusion: GCA‐related CIE such as stroke can be very debilitating and deadly conditions, particularly when GCA is initially diagnosed. However, with early diagnosis and proper management of risk factors, GCA‐related CIE can be prevented and its severity can be reduced. Ischemia in the ophthalmic artery is found to strongly predict GCA‐related CIE while aspirin and antiplatelet agent during the first 3 months may prevent GCA‐related CIE. Risk factors such as BMI and smoking may help in stratifying the risk of GCA‐related CIE. This review underscores the importance of further studies with detailed, well‐designed approaches to risk factor analysis to strengthen these associations. Identifying these risk factors is crucial for reducing morbidity and mortality, equipping physicians to better assess and mitigate the risk of CIE in GCA patients.
- 23 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 176-181
Exploring the Genetic Landscape of Epilepsy With Eyelid Myoclonia: A Comprehensive Review on Clinical Features and Diagnostic Challenges
- 23 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 176-181
Exploring the Genetic Landscape of Epilepsy With Eyelid Myoclonia: A Comprehensive Review on Clinical Features and Diagnostic Challenges
- Open Access
- 10 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5676-5679
‘Tarlatamab’s FDA approval: shaping the future of cancer therapy’
An abstract is unavailable. This article is available as a PDF only.
- 10 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5676-5679
Open Access‘Tarlatamab’s FDA approval: shaping the future of cancer therapy’
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 6 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3201-3203
Crimean-Congo hemorrhagic fever outbreak affecting healthcare workers in Pakistan: an urgent rising concern
An abstract is unavailable. This article is available as a PDF only.
- 6 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3201-3203
Open AccessCrimean-Congo hemorrhagic fever outbreak affecting healthcare workers in Pakistan: an urgent rising concern
An abstract is unavailable. This article is available as a PDF only.
- 29 January 2024
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (2) , 303-311
A clearer vision: insights into juvenile idiopathic arthritis–associated uveitis
The aim of this narrative review is to synthesize existing evidence-based knowledge on juvenile idiopathic arthritis-associated uveitis (JIA-U). We highlight epidemiology, pathophysiology, causes and genetics, risk factors, clinical features, diagnosis and screening, laboratory biomarkers, treatment options, trials with recent advances, and research challenges pertaining to JIA-U. The prevalence of JIA-U varies with different JIA subtypes, most frequently associated with the oligoarticular subtype. The risk factors involved in the development of JIA-U include younger age, antinuclear antibody (ANA) positivity, and the oligoarticular subtype of JIA, along with some specific major histocompatibility complex genes. Certain laboratory biomarkers, such as ANA, rheumatoid factor, interferon-λ, erythrocyte sedimentation rate, and transthyretin, have been used in JIA-U diagnosis, progress monitoring, and prognostication. Clinical features of JIA-U can range from asymptomatic to ophthalmic symptoms like redness, blurred vision, decreased visual acuity, hypopyon, and posterior uveitis, which can lead to retinal detachment and macular edema. The management protocol involves topical and systemic steroids, cycloplegics, disease-modifying antirheumatic drugs, biologic drugs, and surgical options. Early detection combined with prompt treatment is crucial to preventing irreversible vision loss in JIA-U.
- 29 January 2024
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (2) , 303-311
A clearer vision: insights into juvenile idiopathic arthritis–associated uveitis
The aim of this narrative review is to synthesize existing evidence-based knowledge on juvenile idiopathic arthritis-associated uveitis (JIA-U). We highlight epidemiology, pathophysiology, causes and genetics, risk factors, clinical features, diagnosis and screening, laboratory biomarkers, treatment options, trials with recent advances, and research challenges pertaining to JIA-U. The prevalence of JIA-U varies with different JIA subtypes, most frequently associated with the oligoarticular subtype. The risk factors involved in the development of JIA-U include younger age, antinuclear antibody (ANA) positivity, and the oligoarticular subtype of JIA, along with some specific major histocompatibility complex genes. Certain laboratory biomarkers, such as ANA, rheumatoid factor, interferon-λ, erythrocyte sedimentation rate, and transthyretin, have been used in JIA-U diagnosis, progress monitoring, and prognostication. Clinical features of JIA-U can range from asymptomatic to ophthalmic symptoms like redness, blurred vision, decreased visual acuity, hypopyon, and posterior uveitis, which can lead to retinal detachment and macular edema. The management protocol involves topical and systemic steroids, cycloplegics, disease-modifying antirheumatic drugs, biologic drugs, and surgical options. Early detection combined with prompt treatment is crucial to preventing irreversible vision loss in JIA-U.
- 7 November 2023
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (1) , 144-150
Synergistic strategies: Optimizing outcomes through a multidisciplinary approach to clinical rounds
Multidisciplinary rounds (MDR) constitute a patient-centered care model wherein professionals from diverse disciplines collaborate in real time to provide specialized expertise. The MDR team, encompassing care partners, hospitalists, nurses, pharmacists, and more, employs a collaborative approach that optimizes patient care through shared goals, electronic record access, regular reviews, and patient involvement. MDRs have evolved to reduce patient mortality, complications, length of stay, and readmissions, and they enhance patient satisfaction and utilization of ancillary services. Family engagement in MDRs further transforms relationships from adversarial to collaborative, leading to improved comprehension of treatment strategies and smoother navigation of challenging conversations. Despite challenges such as time constraints, limited patient coverage, and hierarchical barriers, MDRs are being increasingly conducted across healthcare settings, with positive outcomes.
- 7 November 2023
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (1) , 144-150
Synergistic strategies: Optimizing outcomes through a multidisciplinary approach to clinical rounds
Multidisciplinary rounds (MDR) constitute a patient-centered care model wherein professionals from diverse disciplines collaborate in real time to provide specialized expertise. The MDR team, encompassing care partners, hospitalists, nurses, pharmacists, and more, employs a collaborative approach that optimizes patient care through shared goals, electronic record access, regular reviews, and patient involvement. MDRs have evolved to reduce patient mortality, complications, length of stay, and readmissions, and they enhance patient satisfaction and utilization of ancillary services. Family engagement in MDRs further transforms relationships from adversarial to collaborative, leading to improved comprehension of treatment strategies and smoother navigation of challenging conversations. Despite challenges such as time constraints, limited patient coverage, and hierarchical barriers, MDRs are being increasingly conducted across healthcare settings, with positive outcomes.
- 5 July 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (7) , e28938
Comment on “Long‐term risk of herpes zoster following COVID‐19: A retrospective cohort study of 2 442 686 patients”
- 5 July 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (7) , e28938
Comment on “Long‐term risk of herpes zoster following COVID‐19: A retrospective cohort study of 2 442 686 patients”